MedImmune LLC

Subsidiary of AstraZeneca (AZN)

Assets

(5 total)
5Total Assets
3Approved
2Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
Type I interferon receptor subunit 1 (IFNAR1)Monoclonal antibody
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis
Benralizumab(Fasenra)
Approved
IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody
Asthma
Approved
CTLA-4Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaBladder CancerBladder / Urothelial Cancer
Urothelial Carcinoma
Phase 3
NKG2AMonoclonal antibody
Non-Small Cell Lung Cancer
Phase 3
CD73Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
TremelimumabPhase 2Hepatocellular Carcinoma
Est. primary completion 2026-11-30 · NCT07081633 · CT.gov ↗
What to watch
December 2026 (1)
Est. primary completion 2026-12-23 · NCT05692180 · CT.gov ↗
What to watch
2027 (2)
January 2027 (1)
AnifrolumabPhase 3Systemic Sclerosis, Scleroderma
Est. primary completion 2027-01-06 · NCT05925803 · CT.gov ↗
What to watch
February 2027 (1)
AnifrolumabPhase 3Lupus Nephritis
Est. primary completion 2027-02-23 · NCT05138133 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
AnifrolumabPhase 3Polymyositis, Dermatomyositis
Est. primary completion 2028-01-10 · NCT06455449 · CT.gov ↗
What to watch
February 2028 (1)
Benralizumab · FasenraPhase 3Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Est. primary completion 2028-02-20 · NCT06512883 · CT.gov ↗
What to watch
August 2028 (1)
AnifrolumabPhase 3Lupus Erythematosus, Systemic
Est. primary completion 2028-08-25 · NCT07751848 · CT.gov ↗
What to watch
October 2028 (1)
AnifrolumabPhase 3Systemic Lupus Erythematosus
Est. primary completion 2028-10-05 · NCT05835310 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
AnifrolumabPhase 3Systemic Lupus Erythematosus
Est. primary completion 2029-01-26 · NCT07430306 · CT.gov ↗
What to watch
December 2029 (1)
Benralizumab · FasenraPhase 3Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Est. primary completion 2029-12-27 · NCT07444567 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
TremelimumabPhase 3Hepatocellular Carcinoma
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
September 2030 (1)
AnifrolumabPhase 2Systemic Lupus Erythematosus
Est. primary completion 2030-09-02 · NCT07630714 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
AnifrolumabPhase 3Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Est. primary completion 2032-12-30 · NCT07691970 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 May 2026Topline resultTremelimumabVOLGA Phase 3 (NCT04960709): perioperative durvalumab plus tremelimumab with neoadjuvant enfortumab vedotin met event-free survival at the interim analysis
Q2 2026Topline resultTremelimumabPhase III NILE: durvalumab plus tremelimumab with chemotherapy missed the overall survival dual primary endpoint
17 September 2025Topline resultBenralizumabRESOLUTE (NCT04053634) Phase 3 missed its primary endpoint
AstraZeneca PLC · Source ↗
17 September 2025Topline resultAnifrolumabPhase III TULIP-SC of subcutaneous anifrolumab met its primary endpoint
AstraZeneca · Source ↗

Financial reports

No financial reports recorded.